Clinical Rheumatology

, Volume 7, Issue 1, pp 46–49

A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease

  • G. T. Sunderland
  • J. J. F. Belch
  • R. D. Sturrock
  • C. D. Forbes
  • A. J. McKay
Originals

DOI: 10.1007/BF02284056

Cite this article as:
Sunderland, G.T., Belch, J.J.F., Sturrock, R.D. et al. Clin Rheumatol (1988) 7: 46. doi:10.1007/BF02284056

Summary

The peripheral vasospastic symptoms associated with Raynaud's disease continue to be an unsolved clinical problem. Hexopal (Hexanicotinate inositol) has shown promise in uncontrolled studies and its use in patients with Raynaud's disease may reduce such vasospasm. This study examines the effects of 4 g/day of Hexopal or placebo, during cold weather, in 23 patients with primary Raynaud's disease. The Hexopal group felt subjectively better and had demonstrably shorter and fewer attacks of vasospasm during the trial period. Serum biochemistry and rheology was not significantly different between the two groups. Although the mechanism of action remains unclear Hexopal is safe and is effective in reducing the vasospasm of primary Raynaud's disease during the winter months.

Key words

Hexopal Controlled Trial Raynaud's Disease 

Copyright information

© Acta Medica Belgica 1988

Authors and Affiliations

  • G. T. Sunderland
    • 1
  • J. J. F. Belch
    • 2
  • R. D. Sturrock
    • 2
  • C. D. Forbes
    • 2
  • A. J. McKay
    • 3
  1. 1.University Department of SurgeryGlasgow Royal InfirmaryGlasgowScotland
  2. 2.University Department of MedicineGlasgow Royal InfirmaryGlasgowScotland
  3. 3.Department of SurgeryGartnavel General HospitalGlasgowScotland
  4. 4.Ninewells HospitalUniversity Department of MedicineDundeeScotland

Personalised recommendations